A new study from Japan reveals a striking pattern: the blockbuster diabetes drugs known as GLP-1 receptor agonists, including Ozempic, are far more effective for people who overeat when food tempts them than for those who turn to food when stressed or upset.
Researchers tracked 92 people with type 2 diabetes over their first year on GLP-1 therapy and found that eating motivation matters as much as the drug itself. Those driven to eat by visual and olfactory cues experienced sustained weight loss and improved blood sugar control. But patients relying on food to soothe emotions saw modest gains that often reversed.
"Pre-treatment assessment of eating behavior patterns may help predict who will benefit most from GLP-1 receptor agonist therapy," said Prof Daisuke Yabe of Kyoto University, the study's senior author. "GLP-1 receptor agonists are effective for individuals who experience weight gain or elevated blood glucose levels due to overeating triggered by external stimuli. However, their effectiveness is less expected in cases where emotional eating is the primary cause."
The findings, published in Frontiers in Clinical Diabetes and Healthcare, matter because millions of people now use GLP-1 drugs to manage diabetes and lose weight. Yet outcomes vary dramatically from person to person, leaving doctors with few tools to predict who will succeed.
Conducted in Gifu Prefecture, the research examined three eating patterns. Emotional eating occurs when people eat to manage negative feelings rather than hunger. External eating happens when appealing food triggers consumption regardless of appetite. Restrained eating involves consciously limiting food to lose weight.
All participants saw gains early on. After three months, they reported eating less in response to emotions and external cues, while restrained eating increased. Weight dropped, body fat fell, and cholesterol improved. Muscle remained stable.
But the pattern fractured by month twelve. Emotional eating rebounded to baseline levels. External eating, however, continued declining steadily through the full year. Participants with the strongest external eating habits at the start showed the largest improvements in weight and blood sugar control.
Dr. Takehiro Kato, second author from Gifu University, explained the divergence: "One possible explanation is that emotional eating is more strongly influenced by psychological factors which may not be directly addressed by GLP-1 receptor agonist therapy. Individuals with prominent emotional eating tendencies may require additional behavioral or psychological support."
The research hints at an uncomfortable truth for the drug industry: a pill cannot rewire how people use food to cope with feelings. While GLP-1 drugs suppress appetite through biological mechanisms, they do not address the emotional drivers of overeating. External eaters, by contrast, simply need reduced hunger signals to change behavior.
Yabe cautioned that the study was observational and relied on self-reported data, so it cannot prove eating behavior caused the different outcomes. Participants were also likely more motivated than average to manage their diabetes. Before doctors screen patients for eating patterns, larger randomized trials will be needed to confirm the link.
"While our study suggests a potential association between external eating behavior and treatment response to GLP-1 receptor agonists, these findings remain preliminary," Yabe said. "Should future large-scale or randomized controlled trials validate this relationship, incorporating simple behavioral assessments could become a valuable component in optimizing treatment strategies."
Author Jessica Williams: "The study is a useful reminder that even wonder drugs have limits, and the most potent medicine is sometimes self-knowledge about why you actually eat."
Comments